These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22161573)

  • 21. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations.
    Akhunzada ZS; Hubert M; Sahin E; Pratt J
    Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of ultraviolet, visible, and infrared light imaging in protein-based biopharmaceutical formulation characterization and development studies.
    Klijn ME; Hubbuch J
    Eur J Pharm Biopharm; 2021 Aug; 165():319-336. PubMed ID: 34052429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interference from Proteins and Surfactants on Particle Size Distributions Measured by Nanoparticle Tracking Analysis (NTA).
    Bai K; Barnett GV; Kar SR; Das TK
    Pharm Res; 2017 Apr; 34(4):800-808. PubMed ID: 28155075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Importance of particle size decrease in the preformulation].
    Szunyogh T; Ambrus R; Szabóné RP
    Acta Pharm Hung; 2011; 81(1):29-36. PubMed ID: 21595303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of an active pharmaceutical ingredient by its dissolution properties: amoxicillin trihydrate as a model drug.
    Horkovics-Kovats S
    Chemotherapy; 2004 Nov; 50(5):234-44. PubMed ID: 15528889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein particulate detection issues in biotherapeutics development--current status.
    Das TK
    AAPS PharmSciTech; 2012 Jun; 13(2):732-46. PubMed ID: 22566174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmasking translucent protein particles by improved micro-flow imaging™ algorithms.
    Pedersen JS; Persson M
    J Pharm Sci; 2014 Jan; 103(1):107-14. PubMed ID: 24281987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products.
    Cash PW; Narwal R; Levitskaya SV; Krause S; Murphy D; Mazaheri M
    PDA J Pharm Sci Technol; 2016; 70(2):134-42. PubMed ID: 26797974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation development of antibody-drug conjugates.
    Galush WJ; Wakankar AA
    Methods Mol Biol; 2013; 1045():217-33. PubMed ID: 23913150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development.
    Rauk AP; Griffiths KL; Gossage MD; Weiss WF
    J Pharm Sci; 2016 Nov; 105(11):3296-3303. PubMed ID: 27663382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence.
    Maddux NR; Daniels AL; Randolph TW
    J Pharm Sci; 2017 May; 106(5):1239-1248. PubMed ID: 28159641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Product development issues for PEGylated proteins.
    Payne RW; Murphy BM; Manning MC
    Pharm Dev Technol; 2011 Oct; 16(5):423-40. PubMed ID: 20858059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Albinterferon α2b adsorption to silicone oil-water interfaces: effects on protein conformation, aggregation, and subvisible particle formation.
    Basu P; Blake-Haskins AW; O'Berry KB; Randolph TW; Carpenter JF
    J Pharm Sci; 2014 Feb; 103(2):427-36. PubMed ID: 24382812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disintegration rate and properties of active pharmaceutical ingredient particles as determined from the dissolution time profile of a pharmaceutical formulation: an inverse problem.
    Horkovics-Kovats S
    J Pharm Sci; 2014 Feb; 103(2):456-64. PubMed ID: 24338791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
    Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid Quantification of Protein Particles in High-Concentration Antibody Formulations.
    Wu H; Randolph TW
    J Pharm Sci; 2019 Mar; 108(3):1110-1116. PubMed ID: 30773198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.